By Michael Dabaie


Sorrento Therapeutics Inc. said the U.S. Food and Drug Administration authorized it to start a Phase 1 clinical trial of its anti-CD38 Dimeric Antigen Receptor-T Cell therapy for relapsed or refractory multiple myeloma.

The proprietary CD38 DAR-T cell therapy candidate demonstrated strong cytotoxic activity in preclinical studies, the company said.

Sorrento said the DAR-T technology is readily adaptable to dozens of cancer targets.


Write to Michael Dabaie at


(END) Dow Jones Newswires

August 02, 2021 09:46 ET (13:46 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.